Coronary heart disease and chronic kidney disease: the possibilities of PCSK9 inhibitors in the achievement of atherogenic lipoproteins target values

Coronary heart disease and chronic kidney disease: the possibilities of PCSK9 inhibitors in the achievement of atherogenic lipoproteins target values

Objective: Possibilities evaluation of achieving the target values of atherogenic lipoproteins in patients with coronary heart disease (CHD) in combination with renal dysfunction during drug correction with PCSK9 inhibitors.Material and methods: The study included 76 men with CHD with very high card...

Full description

Bibliographic Details
Main Authors:	G. S. Mal, A. A. Kuznetsov
Format:	Article
Language:	Russian
Published:	Scientific Research Institute, Ochapovsky Regional Clinical Hospital no. 1 2022-06-01
Series:	Инновационная медицина Кубани
Subjects:	coronary heart disease chronic kidney disease pcsk9 inhibitors alirocumab
Online Access:	https://www.innovmedkub.ru/jour/article/view/532

Similar Items

Comparative effectiveness of different methods of prescribing rosuvastatin and ezetimibe in combination with PCSK9 inhibitors
by: A. A. Kuznetsov, et al.
Published: (2024-06-01)

Analysis of The Use of PCSK9 Inhibitors in Clinical Practice
by: S. Yu. Volkova, et al.
Published: (2023-03-01)

PCSK9-antibodies fail to block PCSK9-induced inflammation in macrophages and cannot recapitulate protective effects of PCSK9-deficiency in experimental myocardial infarction
by: Simon Rauterberg, et al.
Published: (2025-01-01)

PCSK9 inhibitors for in-hospital treatment of patients with acute coronary syndrome and severe lipid metabolism disorders
by: O. L. Barbarash, et al.
Published: (2020-09-01)

PCSK9 Inhibition: Insights From Clinical Trials and Future Prospects
by: Julius L. Katzmann, et al.
Published: (2020-11-01)

The wind of change – PCSK9 inhibitors in hypolipidemic treatment. The Polish perspective
by: Natalia Ilnicka, et al.
Published: (2023-09-01)

New opportunities for lowering low-density lipoprotein cholesterol: comparative characteristics of PCSK9-targeted therapy
by: S. K. Zyryanov, et al.
Published: (2022-12-01)

PCSK9 Monoclonal Antibodies for the Primary and Secondary Prevention of Cardiovascular Disease
by: article Editorial
Published: (2023-12-01)

Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery Disease
by: Fei Gao, et al.
Published: (2022-05-01)

Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients With Hypercholesterolemia: A Meta‐Analysis of 35 Randomized Controlled Trials
by: Aris Karatasakis, et al.
Published: (2017-12-01)

An Analysis of the Gut Microbiota and Related Metabolites following PCSK9 Inhibition in Statin-Treated Patients with Elevated Levels of Lipoprotein(a)
by: Jose A. Caparrós-Martín, et al.
Published: (2024-01-01)

Statin administration or blocking PCSK9 alleviates airway hyperresponsiveness and lung fibrosis in high-fat diet-induced obese mice
by: Lin Liang, et al.
Published: (2024-05-01)

PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
by: Blom DJ, et al.
Published: (2016-05-01)

Real-world use of PCSK-9 inhibitors by early adopters: cardiovascular risk factors, statin co-treatment, and short-term adherence in routine clinical practice
by: Fairman KA, et al.
Published: (2017-08-01)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
by: Marina Blanco-Ruiz, et al.
Published: (2021-11-01)

Effect of alirocumab on cataracts in patients with acute coronary syndromes
by: Gaspard Suc, et al.
Published: (2023-06-01)

Association between PCSK9 inhibitors and acute kidney injury: a pharmacovigilance study
by: Hailing Liu
Published: (2024-08-01)

Real-world safety of PCSK9 inhibitors: A pharmacovigilance study based on spontaneous reports in FAERS
by: Zhen Feng, et al.
Published: (2022-11-01)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

Polymorphic Variant rs11206510 in PCSK9 and Risk of Coronary Artery Disease in Bulgarians
by: Tzveova R., et al.
Published: (2023-04-01)

PCSK9: NEW VICTORY AND HORIZONS
by: M. O. Smolina, et al.
Published: (2018-09-01)

The Role of PCSK9 Inhibitors in the Improvement of Outcomes in Patients after Acute Coronary Syndrome: Results of ODYSSEY OUTCOMES Trial
by: Yu. A. Karpov
Published: (2019-01-01)

Leptin and PCSK9 concentrations are associated with vascular endothelial cytokines in patients with stable coronary heart disease
by: Wang Qiang, et al.
Published: (2022-01-01)

A spotlight on alirocumab in high cardiovascular risk patients with type 2 diabetes and mixed dyslipidemia: a review on the emerging data
by: Rana K, et al.
Published: (2019-09-01)

Observational multicentre prospective study to assess changes in cognitive function in patients treated with PCSK9i. Study protocol
by: José Seijas-Amigo, et al.
Published: (2021-05-01)

Intensification of lipid-lowering therapy in very high-risk patients: potential of combination with PCSK9 inhibitors
by: D. Yu. Sedykh, et al.
Published: (2022-07-01)

PCSK9 inhibitors and inclisiran with or without statin therapy on incident muscle symptoms and creatine kinase: a systematic review and network meta-analysis
by: Wenshu Li, et al.
Published: (2024-07-01)

Effect of PCSK9 Inhibitors on Regulators of Lipoprotein Homeostasis, Inflammation and Coagulation
by: Patricija Lunar, et al.
Published: (2025-01-01)

Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus
by: Juan Huang, et al.
Published: (2023-12-01)

Proprotein Convertase Subtilisin Kexin 9 Inhibitor in Severe Sepsis and Septic Shock Patients in a Phase II Prospective Cohort Study—Preliminary Results
by: Ziv Rosman, et al.
Published: (2024-10-01)

Insight into the Evolving Role of PCSK9
by: Mateusz Maligłówka, et al.
Published: (2022-03-01)

Alirocumab Administration Experience to Achieve Low Density Lipoprotein Cholesterol Target Levels in Secondary Prevention of Cardiovascular Disease
by: A. E. Nikitin, et al.
Published: (2020-03-01)

Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors
by: Paul C Langley, Dr
Published: (2017-05-01)

Ossabaw Pigs With a PCSK9 Gain‐of‐Function Mutation Develop Accelerated Coronary Atherosclerotic Lesions: A Novel Model for Preclinical Studies
by: Fang Yuan, et al.
Published: (2018-03-01)

Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
by: Chandni Bardolia, et al.
Published: (2021-11-01)

Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors
by: Katja Hrovat, et al.
Published: (2022-07-01)

PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD)
by: Saeideh Sobati, et al.
Published: (2020-08-01)

Impact of national drug price negotiation policy on the accessibility and utilization of PCSK9 inhibitors in China: an interrupted time series analysis
by: Lingli Zhang, et al.
Published: (2024-06-01)

Impact of early PCSK9 inhibitor treatment on heart after percutaneous coronary intervention in patients with STEMI: Design and rationale of the PERFECT II trial
by: Jiachun Xia, et al.
Published: (2022-09-01)

What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials
by: Remo H. M. Furtado, et al.
Published: (2020-02-01)